Aktis Oncology, Inc. · NASDAQ:AKTS
Aktis Oncology — Corporate Update (May 2026)
25 slides from Aktis Oncology's corporate update, May 27, 2026
Slide 1: AKY-2519 Clinical Imaging and Dosimetry Data
AKY-2519 Clinical Imaging and Dosimetry Data May 27, 2026
Slide 2: Disclaimer
Disclaimer Information in this presentation and the accompanying oral presentation contains forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 that involve substantial risks and uncertainties about Aktis Oncology and the industry in which Aktis Oncology op
Slide 3: Agenda
Agenda Aktis Corporate Overview & Upcoming Milestones B7-H3 Overview & AKY-2519 Clinical Imaging and Dosimetry Data Fireside Chat with Oliver Sartor, M.D., and Timothy Yap, MBBS, Ph.D. 3
Slide 4: Maximizing the impact of radiopharmaceuticals
Maximizing the impact of radiopharmaceuticals Novel and Differentiated Platform Two Clinical Programs Accomplished Addressing Large Market Leadership Team Tumor Types Strong Imaging Proof-of- Balance Sheet Concept in Patients Pillars of value Pipeline Isotope Supply of Potential First-in- from Multi
Slide 5: Significant opportunity for B7-H3 as a differentiated radiopharmaceutical target in mCRPC and other indications
Significant opportunity for B7-H3 as a differentiated radiopharmaceutical target in mCRPC and other indications • PLUVICTO® estimated global peak sales B7-H3 is highly expressed in multiple solid tumors; ~$5.4 billion in prostate cancer alone1 Potential to unlock whitespace opportunities • Persisten
Slide 6: Patient-centric approach to maximizing radiopharmaceutical impact
Patient-centric approach to maximizing radiopharmaceutical impact GOAL TO MAXIMIZE PATIENT BENEFIT DESIGNED TO EXPAND RADIOPHARMACEUTICAL IMPACT Isotope-agnostic to Drive efficacy image and treat Non-cleavable linker Widen safety window Folded miniprotein target binder (~40-60aa) Address more target
Slide 7: Aktis is advancing a novel pipeline for large patient populations
Aktis is advancing a novel pipeline for large patient populations PROGRAM TARGET/INDICATION DISCOVERY IND-ENABLING PHASE 1b PHASE 2/3 UPCOMING MILESTONES Nectin-4 expressing Ph1b ongoing AKY-1189 Fast Track Designation* solid tumors Prelim data in 1Q’27 Imaging/ dosimetry data at ASCO 2026 B7-H3 exp
Slide 8: Clinical imaging and dosimetry data for AKY-2519 to be presented at the 2026 ASCO Annual Meeting
Clinical imaging and dosimetry data for AKY-2519 to be presented at the 2026 ASCO Annual Meeting AKY-2519, a novel B7-H3-targeted radioconjugate, and its biodistribution profile in patients with mCRPC* DATE AND TIME: May 30, 1:30 p.m. - 4:30 p.m. CDT support ongoing PRESENTER: Michael Sathekge, Prof
Slide 9: Multiple anticipated milestones over the next 12 months
Multiple anticipated milestones over the next 12 months 2026 2027 MAY’26 MAY'26 2H’26 2027 AKY-2519 (B7-H3) mCRPC Ph1b Clinical imaging and Basket Ph1b trial start Prelim data from Ph1b trial start dosimetry data - ASCO mCRPC trial in 2027 1Q’27 Ph1b prelim data AKY-1189 (Nectin-4) 2H’26 1Q’27 Corpo
Slide 10: B7-H3 Overview & AKY-2519 Clinical Imaging and Dosimetry Data
B7-H3 Overview & AKY-2519 Clinical Imaging and Dosimetry Data
Slide 11: AKY-2519 is a novel miniprotein radioconjugate designed to target B7-H3 Expressing Tumors
AKY-2519 is a novel miniprotein radioconjugate designed to target B7-H3 Expressing Tumors [225Ac]Ac-AKY-2519 RCT binds to B7-H3 on tumor cells (A) and results in cell death through radioactive decay (B) A B • High affinity binding to B7-H3 (KD = 0.45 ±0.17 nM) • Selective B7-H3 binding with no off-t
Slide 12: B7-H3 is a clinically-validated high-potential multi-tumor target
B7-H3 is a clinically-validated high-potential multi-tumor target TUMOR Tum. cells NORMAL TISSUE Normal Vessels & vessels Brain Breast Colon Kidney • B7-H3 is highly expressed in various solid tumors, including mCRPC, lung cancer and Lung breast cancer, and shows minimal expression in normal organs1
Slide 13: Key takeaways from the clinical imaging and dosimetry data for AKY-2519
Key takeaways from the clinical imaging and dosimetry data for AKY-2519 AKY-2519 was generally well tolerated, with no reported adverse events or infusion-related reactions Observed robust tumor doses paired with low predicted doses to critical normal tissues, suggest a wide therapeutic index for th
Slide 14: AKY-2519 Early Human Imaging Assessment Workflow
AKY-2519 Early Human Imaging Assessment Workflow 34 patients imaged across 2 academic sites in South Africa and Europe 16 patients with mCRPC at NuMeRI 18 patients with prostate, lung, colorectal, & other tumor types at Pretoria, South Africa at University Hospital Essen, Essen, Germany [68Ga]Ga-AKY
Slide 15: AKY-2519 demonstrates robust tumor uptake and retention with predicted absorbed doses suggesting a wide therapeutic index
AKY-2519 demonstrates robust tumor uptake and retention with predicted absorbed doses suggesting a wide therapeutic index A PET/CT B SPECT/CT E % COVERAGE F Mean Absorbed Dose Predicted Dosea SECT/CT AXIAL IMAGES AT 24 HOURS Region of Interest Coefficient (225Ac) at MBq x 4 GyRBE=5/MBq GyRBE=5 Invol
Slide 16: Administration of AKY-2519 was generally well tolerated and predicts normal tissue doses below established clinical benchmarks
Administration of AKY-2519 was generally well tolerated and predicts normal tissue doses below established clinical benchmarks Predicted [225Ac]Ac-AKY-2519 absorbed doses in critical normal tissues Mean Absorbed Dose Predicted Absorbed Normal Tissue Coefficient (225Ac) Dose at 8 MBq x 4 • Normal tis
Slide 17: AKY-2519 demonstrates robust tumor uptake and retention with predicted absorbed doses suggesting a wide therapeutic index
AKY-2519 demonstrates robust tumor uptake and retention with predicted absorbed doses suggesting a wide therapeutic index • Predicted absorbed doses to selected tumors, including the involved prostate and seminal vesicles, as well as nodal and bony metastases, are within expected therapeutic ranges
Slide 18: [68Ga]Ga-AKY-2519 demonstrates robust tumor uptake in a variety of solid tumors
[68Ga]Ga-AKY-2519 demonstrates robust tumor uptake in a variety of solid tumors Representative patients across solid tumor types with robust tumor uptake at 120 minutes following [68Ga]Ga-AKY-2519 administration • Uptake of [68Ga]Ga-AKY- 2519 was observed across multiple tumor types at various time
Slide 19: [68Ga]Ga-AKY-2519 uptake was consistently observed at high levels across metastatic disease sites
[68Ga]Ga-AKY-2519 uptake was consistently observed at high levels across metastatic disease sites in patients with prostate cancer • Summary data was compiled for the largest cohort of patients (mHSPC/mCRPC) across multiple ROIs. • Consistently high SUV values were observed across metastatic sites,
Slide 20: [68Ga]Ga-AKY-2519 consistently identifies lesions also identified by [68Ga]Ga-PSMA-11
[68Ga]Ga-AKY-2519 consistently identifies lesions also identified by [68Ga]Ga-PSMA-11 A [68Ga]Ga-PSMA-11 [68Ga]Ga-AKY-2519 B [68Ga]Ga-PSMA-11 [68Ga]Ga-AKY-2519 PATIENT A 60 min 60 min 120 min PATIENT B 60 min 60 min 120 min 20
Slide 21: Key takeaways from the clinical imaging and dosimetry data for AKY-2519
Key takeaways from the clinical imaging and dosimetry data for AKY-2519 AKY-2519 was generally well tolerated, with no reported adverse events or infusion-related reactions Observed robust tumor doses paired with low predicted doses to critical normal tissues, suggest a wide therapeutic index for th
Slide 22: Ongoing mCRPC-dedicated Phase 1b trial designed to rapidly generate data in PLUVICTO-naïve and -experienced patients
Ongoing mCRPC-dedicated Phase 1b trial designed to rapidly generate data in PLUVICTO-naïve and -experienced patients AKY-2519-02 Trial design Dose escalation: BOIN Backfill (n ≈ 30/cohort; escalation pts included) 12 MBq THERAPY THERAPY Backfill Dose 1 PLUVICTO-naïve [225Ac]Ac-AKY-2519 [225Ac]Ac-AKY
Slide 23: On track to initiate B7-H3 basket trial in 2H'26
On track to initiate B7-H3 basket trial in 2H’26 AKY-2519-02 Trial design PART 1 PART 2 Dose escalation: BOIN (n = up to 18) Backfill (n = up to 60) Dose expansion (n = up to 70) 12 MBq 2L(+) NSCLC Cohort 1 BACKFILL THERAPY Dose 1 [225Ac]Ac-AKY-2519 2L(+) NSCLC THERAPY 2L(+) Other (n=31) [225Ac]Ac-A
Slide 24: Fireside Chat
Fireside Chat Akos Czibere, Oliver Sartor, Timothy A. Yap, MD, Ph.D. MD MBBS, Ph.D. Chief Medical Officer Director Vice President and Head of Clinical Development, Aktis Oncology Transformational Prostate Cancer Therapeutics Discovery Division; Professor, Research Center at LCMC Health Department of
Slide 25: Thank You
Thank You — =